North East and North Cumbria
ICS Formulary
 
back
8 Malignant disease and immunosuppression
08-01-05 Erlotinib

Erlotinib
Formulary
  • Also approved for second line use, as an alternative to docetaxel, in NSCLC in line with NICE.
  • Monotherapy not approved for maintenance after platinum chemotherapy in advanced or metastatic NSCLC NICE.
  • Approved for the treatment of locally advanced or metastatic nonsmall-cell lung cancer that has already been treated with non-targetted chemotherapy because of delayed confirmation of epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation status if; their cancer tests positive for EGFR-TK mutation; it is not know if the cancer is EGFR-TK mutation- positive because of problems with the test, and the cancer is very likely to be EGFR-TK mutation-positive and it responds to the first 2 cycles of treatment with erlotinib - in line with NICE.
Link  NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Link  Roche Healthcare Professional Letter (January 2016): Tarceva (erlotinib)
Link  MHRA Drug Safety Update (May 2012): Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis

Red View adult BNF  View SPC online  View childrens BNF